MTCH
26
-7
MMM
44
2
CNP
49
7
GOOG
71
-6
PSA
60
5
KR
52
2
CRM
67
2
LLY
50
11
FLR
52
-17
CCL
86
2
EQIX
65
3
OKE
80
2
ICE
59
2
ZTS
47
7
HIG
64
5
O
35
4
BRK.B
40
2
LMT
39
4
SNA
70
-2
PYPL
52
2
MTCH
26
-7
MMM
44
2
CNP
49
7
GOOG
71
-6
PSA
60
5
KR
52
2
CRM
67
2
LLY
50
11
FLR
52
-17
CCL
86
2
EQIX
65
3
OKE
80
2
ICE
59
2
ZTS
47
7
HIG
64
5
O
35
4
BRK.B
40
2
LMT
39
4
SNA
70
-2
PYPL
52
2
Financhill
Back

Zevra Therapeutics 10K Form

Buy
67

ZVRA
Zevra Therapeutics

Last Price:
9.00
Seasonality Move:
-2.11%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ZVRA News And Ratings

See the #1 stock for the next 7 days that we like better than ZVRA

ZVRA Financial Statistics

Sales & Book Value

Annual Sales: $27.46M
Cash Flow: $-19.11M
Price / Cash Flow: 0
Annual Sales: $0.77
Price / Book: 14.58

Profitability

EPS (TTM): -1.68000
Net Income (TTM): $-65.75M
Gross Margin: $24.52M
Return on Equity: -117.77%
Return on Assets: -46.14%

Zevra Therapeutics Earnings Forecast

Key Zevra Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for ZVRA is 89.28%.
  • The Selling, General & Administrative Expenses for ZVRA have been equal to 124.96% of Gross Profit Margin.
  • The Research & Development expenses have been 144.95% of Revenue.
  • The Interest Expense is -3.26% of Operating Income.
  • The Net Earning history of ZVRA is -167.69% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Zevra Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ZVRA
Website: zevra.com

Debt

Debt-to-Equity Ratio: 1.8
Current Ratio: 2
Quick Ratio: 1.91

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ZVRA Technical Analysis vs Fundamental Analysis

Buy
67
Zevra Therapeutics (ZVRA) is a Buy

Is Zevra Therapeutics a Buy or a Sell?